First patient dosed in Axsome’s FOCUS-3 trial of solriamfetol for ADHD

Axsome Therapeutics has dosed the first patient its FOCUS-3 Phase III clinical trial assessing solriamfetol in adolescents with ADHD. The double-blind, randomised, multicentre, placebo-controlled study aims to enrol around 468 patients. ADHD is a chronic neurobiological and developmental disorder. Credit: Inna Kot/Shutterstock.com. Axsome Therapeutics has dosed the first patient in its FOCUS-3 Phase III clinical trial assessing solriamfetol in adolescents with attention deficit hyperactivity disorder (ADHD). The double-blind, randomised, multicentre, placebo-controlled trial will evaluate the efficacy and safety of solriamfetol in adolescents aged 12 to less than 18 years who have ADHD. LOA and PTSR Model Centanafadine Sr in…

Source: Clinical Trials Arena